SCHEMBL31408586

SCHEMBL31408586

CNc1ccc(-c2cc3[nH]c(CNC(C)=O)cc3cc2Cl)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MTNR1A P48039 4/20 0.39
▸ MTNR1B P49286 4/20 0.39
▸ TDO2 P48775 3/20 0.39
▸ PRKAG1 P54619 3/20 0.37
▸ PRKAA1 Q13131 3/20 0.37
▸ PRKAB1 Q9Y478 3/20 0.37
▸ PRKAB2 O43741 1/20 0.37
▸ PRKAA2 P54646 1/20 0.37
▸ PRKAG3 Q9UGI9 1/20 0.37
▸ PRKAG2 Q9UGJ0 1/20 0.37
▸ ABL1 P00519 1/20 0.36
▸ MAPT P10636 3/20 0.36
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ NNMT P40261 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408372 0.90 TDO2 (0.39) SMN1; SMN2MTNR1AMTNR1BTDO2PRKAG1
SCHEMBL31408611 0.86 SMN1; SMN2 (0.41) SMN1; SMN2MTNR1AMTNR1BTDO2PRKAG1
SCHEMBL31408394 0.85 SMN1; SMN2 (0.38) SMN1; SMN2MTNR1AMTNR1BMAPTNNMT
SCHEMBL31408238 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MTNR1AMTNR1BPRKAG1PRKAA1
SCHEMBL31408351 0.85 SMN1; SMN2 (0.40) SMN1; SMN2MTNR1AMTNR1BPRKAG1PRKAA1
SCHEMBL31408250 0.84 PRKAG1 (0.48) SMN1; SMN2MTNR1AMTNR1BTDO2PRKAG1
SCHEMBL31408354 0.84 PRKAG1 (0.48) SMN1; SMN2MTNR1AMTNR1BPRKAG1PRKAA1
SCHEMBL31408506 0.84 SMN1; SMN2 (0.39) SMN1; SMN2MTNR1AMTNR1BPRKAG1PRKAA1
SCHEMBL31408545 0.84 PTGES (0.46) SMN1; SMN2MTNR1AMTNR1BPRKAG1PRKAA1
SCHEMBL31408259 0.83 SMN1; SMN2 (0.40) SMN1; SMN2MTNR1AMTNR1BMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049604-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback